NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say ...
Sanofi has tipped three “pipeline-in-a-product” assets to generate 5 billion euros ($5.4 billion) a year or more. The forecasts are part of a set of predictions intended to justify the drugmaker’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback